CrisprBits Teams Up With Molbio For CRISPR POC Tests
Written by Arushi Sharma, Susi
The dynamic collaboration between CrisprBits and Molbio signifies a pivotal step forward in the realm of diagnostic testing. By combining their expertise, these two industry leaders are working together to create revolutionary point-of-care (POC) tests based on CRISPR technology.
CrisprBits, a CRISPR gene-editing biotech startup, has collaborated with Molbio Diagnostics to develop CRISPR-based Point-of-Care (POC) testing.
The collaboration aims to leverage their strengths for rapid, accurate, and affordable POC tests via CrisprBits' PathCrisp platform, with Molbio handling manufacturing, sales, and distribution globally.
Dr Vijay Chandru, Chief Scientific Officer and Co-founder, CrisprBits said,
“The reimagination of health systems in India has to ride on a central role played by “pervasive” diagnostic tests POCTs (Point-of-care tests) that are light on instruments, affordable and designed for ease of use by community health workers. This would enable better preventive care and early detection interventions in treatment.
This innovation has to be driven in the LMICs (Low and Middle Income Countries) as developed economies have legacy infrastructure that addresses these issues with access to labs or clinics at a different scale. By teaming up with Molbio Diagnostics, we are combining our innovations in instrument-light CRISPR POCTs to develop and distribute a new generation of tests that are pervasive and will enable early detection and timely treatment.”
The collaboration seeks to develop POCTs for on-site detection of pathogens and genetic markers. These tests will be available in clinics, hospitals, and resource-constrained areas, meeting critical diagnostic needs.
Dr Chandrashekar Nair, Chief Technical Officer, Molbio Diagnostics said,
“We are very excited about this partnership with CrisprBits. The coming together of their innovation and Molbio’s strengths in translation, manufacturing and distribution has the potential to rapidly provide cutting edge diagnostics solutions where it is required the most. This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally.”
Sunil Arora, Co-Founder and CEO, CrisprBits, said in a statement said,
“CrisprBits was established with a clear mission to tackle crucial healthcare challenges by harnessing the groundbreaking potential of CRISPR technology. By partnering with Molbio diagnostics we strive to bring to these tests that impact real-time decision-making that leads to enhanced patient outcomes and more effective public health management.”
The collaboration seeks to develop POCTs for on-site detection of pathogens and genetic markers. These tests will be available in clinics, hospitals, and resource-constrained areas, meeting critical diagnostic needs.